As you point out, there is more money being put into research employees and organisational structure. That’s a good thing but it has come about because of rapidly increasing revenue.
The company has chosen to weight expenditure to sales and marketing because it has an approved product (BTM) that has a global market where success is truly company making. Success in that market would not have been as good as it has been if the company had instead weighted research expenditures higher.
Medtronic has entered the market for resorbable mesh Ventral Hernia Repair, page-15
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.53 |
Change
-0.015(0.59%) |
Mkt cap ! $1.746B | |||
| Open | High | Low | Value | Volume |
| $2.55 | $2.56 | $2.50 | $1.681M | 664.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 18351 | $2.52 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.53 | 33097 | 21 |
View Market Depth
| Last trade - 14.50pm 13/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |